– USA, CA – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the appointment of Alex M. Azar II to its board of directors, effective immediately.
About Alex M. Azar II
As the 24th Secretary of the U.S. Department of Health and Human Services, Secretary Azar had oversight and management of agencies critical to all Americans’ health care, including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and theCentersr for Disease Control and Prevention.
Before he was appointed HHS Secretary, Azar held multiple executive leadership roles, including as President of Lilly USA, LLC, the largest affiliate of Eli Lilly and Company, General Counsel of HHS, Deputy Secretary of HHS, and Partner at Wiley Rein LLP. He currently serves as an Adjunct Professor of Business and Distinguished Executive-in-Residence at the University of Miami Patti and Allan Herbert Business School. He also serves as a member of the Board of Trustees at the Aspen Institute, chairman of the board of LifeScience Logistics, a member of the boards of Global Health/MCS, AbsoluteCare, and Interwell Health, and as an advisor at Foresite Capital, a member of the advisory board of Milken Institute’s FasterCures, and a member of the Department of Health Policy Advisory Board at the Stanford University School of Medicine.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
For more: https://guardanthealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.